2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMORecruiting
The objective of this study is to investigate the added effect of an intramuscular (IM) gluteal corticosteroid injection above a placebo IM gluteal injection (saline) on pain symptoms in patients with hip OA, not responding satisfactory to the usual…